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A B S T R A C T
The complement system has obtained renewed clinical focus due to increasing number of patients treated with
eculizumab, a monoclonal antibody inhibiting cleavage of C5 into C5a and C5b. The FDA approved indications
are paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome, but many other diseases
are candidates for complement inhibition. It has been postulated that eculizumab does not inhibit C5a formation
in vivo, in contrast to what would be expected since it blocks C5 cleavage. We recently revealed that this finding
was due to a false positive reaction in a C5a assay. In the present study, we identified expression of a neoepitope
which was exposed on C5 after binding to eculizumab in vivo. By size exclusion chromatography of patient serum
obtained before and after infusion of eculizumab, we document that the neoepitope was exposed in the fractions
containing the eculizumab-C5 complexes, being positive in this actual C5a assay and negative in others.
Furthermore, we confirmed that it was the eculizumab-C5 complexes that were detected in the C5a assay by
adding an anti-IgG4 antibody as detection antibody. Competitive inhibition by anti-C5 antibodies localized the
epitope to the C5a moiety of C5. Finally, acidification of C5, known to alter C5 conformation, induced a
neoepitope reacting identical to the one we explored, in the C5a assays. These data are important for inter-
pretation of complement analyses in patients treated with eculizumab.
1. Introduction
Complement inhibitory therapy has reached the clinic as an in-
creasing number of patients are treated with the humanized mono-
clonal IgG2/4 chimeric anti-complement C5 inhibitor eculizumab,
particularly those with the FDA approved diagnoses of paroxysmal
nocturnal haemoglobinuria and atypical haemolytic uremic syndrome
(Hillmen et al., 2006; Legendre et al., 2013). A number of assays have
already been developed by our and others’ groups, to detect comple-
ment activation in vivo by antibodies to neoepitopes (Harboe et al.,
2011), (Mollnes et al., 2007). In patients, these techniques are im-
portant for evaluating ongoing complement activation, and thus
whether complement inhibitory treatment is indicated and if treatment
is effective. Previously, we documented that a C5a neoepitope appeared
in plasma from patients treated with eculizumab, but without cleavage
of C5 into C5a and C5b (Volokhina et al., 2015). Remodelling of C5,
independent on cleavage, with exposure of neoepitopes, appears in C5
upon e.g. serum acidification or treatment with reactive oxygen meta-
bolites (Hammer et al., 1983; von Zabern et al., 1987). Here, we
document that C5a detected in plasma from eculizumab treated patents
was due to false positive reaction in the BD C5a assay, not recognizing
C5a, but a neoepitope exposed after a conformational change of native
C5 upon binding to eculizumab.
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Whole blood was collected, with informed consent according to the
Declaration of Helsinki, from twenty healthy individuals, from a genetic
C5-deficient individual (Lappegard et al., 2009), and from a patient
with antiphospholipid syndrome prior to and after administration of
eculizumab. Serum was prepared by clotting for 60 min and im-
mediately stored at −80 °C.
2.2. Size-exclusion chromatography and detection of C5, eculizumab and
complexes thereof
Patient serum (PS) pre- and post-eculizumab administration were
fractionated on an ENrich™ size-exclusion column 650 (Bio-Rad
Laboratories Inc., Hercules, CA) using a NGC Quest™ 10 (Bio-Rad)
chromatography system. Dulbecco’s PBS (Sigma-Aldrich, St. Louis, MO)
with 10 mM EDTA was used as running buffer at 1 mL/minute; 0.5 mL
fractions were collected. Elution volume was related to a molecular
weight standard (#1511901, Bio-Rad). Serum fractions were incubated
overnight on microtiter plates (Nunc MaxiSorp, Nunc, Roskilde,
Denmark) and C5 and IgG4 were detected in coated fractions by specific
antibodies (rabbit anti-human C5, Complement Technologies, Tyler, TX
and mouse anti-human IgG4, clone HP6025, Southern Biotech,
Birmingham, AL). C5a was detected in fractionated serum by C5a ELISA
kits (BD OptEIA™ from BD Bioscience, San Jose, CA; and Hycult
Biotech, Uden the Netherlands). For reference, complement activated
NHS (Bergseth et al., 2013) was fractionated as for PS described above.
To prove that it was eculizumb-C5 complexes that were detected in the
BD C5a assay, we replaced the anti-C5a detection antibody with the
anti-IgG4 antibody.
2.3. Induction of C5a neoepitope
NHS and genetic C5 deficient serum were acidified to pH 6.8 and
6.4 by addition of 5% (v/v) 0.33 M and 0.50 M sterile HCl respectively.
After 15 min incubation in room temperature, C5a was quantified in
acidified and unmodified serum (pH 7.4) by the C5a ELISAs from BD
and Hycult. In separate experiments different well characterized
monoclonal antibodies (20 μg/mL) against C5 were preincubated with
NHS (pH 6.4–7.4): clones 137-30 and 137-26 (Fung et al., 2003) (a kind
gift from Michael Fung), clone C17/5 (Oppermann et al., 1991) (a kind
gift from Martin Oppermann) and mAb anti-C5 #A217 (Quidel, San
Diego, CA), in order to localize the site of the neoepitope by competitive
inhibition.
3. Results and discussion
Eculizumab binds C5 and prevents cleavage into C5b and C5a,
possibly by sterically hindering the association of C5 to the C5-con-
vertase (Jore et al., 2016; Schatz-Jakobsen et al., 2016). We recently
showed that administration of eculizumab to three patients induced a
false-positive C5a signal in plasma detected with BD C5a ELISA
(Volokhina et al., 2015). No C5a was detected in corresponding C5a
ELISAs from Hycult or RnD. Also sC5b-9 showed baseline values,
clearly supporting fully blocked C5 cleavage. Here, we characterize the
actual epitope reacting in the BD C5a assay and show that eculizumab
binding to C5 in vivo induces a conformational change with exposure of
a C5a neoepitope without C5 cleavage, but detected in the actual assay.
Patient serum (PS) before (PS-PRE) and after (PS-POST) first time
infusion of eculizumab were fractionated by size-exclusion chromato-
graphy. IgG4 and C5 eluted as single peaks in both samples corre-
sponding to their molecular weight (IgG 150 and C5 190 kDa)
(Fig. 1A–B). In PS-POST, eculizumab-C5 complexes, detected by both
anti-IgG4 and anti-C5 antibodies, eluted as a high-molecular weight
peak (rage 340–530 kDa), consistent with both monovalent and biva-
lent C5 binding (Fig. 1A–B).
All fractions were analysed for C5a by using the BD and Hycult C5a
ELISAs (Fig. 1C). C5a (10 kDa) was not detected in any of the low
molecular weight fractions (< 150 kDa) but the eculizumab-C5 com-
plex rendered a distinct signal in the BD C5a-ELISA, which was not
detected in the Hycult C5a-ELISA, documenting that the BD C5a-ELISA
reacts to a C5a neoepitope exposed in the eculizumab-C5 complex.
Replacing the anti-C5a detection antibody in the BD assay with an anti-
IgG4 antibody confirmed that it was the eculizumab-C5 complex that
was detected, since the optical density was 2–3 logs higher in the
sample from the eculizumab treated patient than the values observed in
normal serum. Conformational remodelling in proteins upon ligand
interaction is not unexpected. Jore et al. recently showed that two small
protein-based C5-inhibitors, both binding distal to the C5a domain,
induced remodelling of the C5a domain (Jore et al., 2016). Our data
indicates that eculizumab does the same, and assays used for
Fig. 1. Size-exclusion chromatography for the identification of C5a in patient treated
with eculizumab. (A–C). A patient serum (PS) samples pre- and post- (PS-PRE and PS-
POST, respectively) first time infusion of eculizumab were subjected to fractionation by
size-exclusion chromatography. Fractions (0.5 mL) were collected at a flow rate of 1 mL/
minute and coated on microtiter plates. Polyclonal antibodies against IgG4 (A) and C5 (B)
were employed for detection of eculizumab (IgG2/4 chimeric antibody), C5 and eculi-
zumab-C5 complexes (E-C5) in the coated fractions. (C) The fractions were tested in the
BD and Hycult C5a-ELISAs, showing reactivity of the E-C5 complexes in the PS-POST
sample only in the BD assay (upper panel). A positive control to show true C5a reactivity
in human serum was included by fractionating normal human serum (NHS) activated
with zymosan and heat aggregated IgG (activated NHS), being positive in both assays
(these values were diluted 10 times compared to the factions of patient sera in order to get
comparable peaks).
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quantification of C5a should be carefully checked for reactivity against
C5 bound to eculizumab and be avoided when analysing samples from
patients treated with C5 inhibitors.
C5 is prone to conformational change during stress, induced e.g. by
acidification (Hammer et al., 1983), freeze-thawing (Dessauer et al.,
1984), or by oxidative reagents (von Zabern et al., 1987) thus adopting
a “C5b-like” conformation which is able to bind C6, however without
liberation of C5a (Vogt et al., 1989). Here we quantified C5a in NHS
and in C5 deficient serum at pH 7.4 and in pH-modified serum (pH 6.8
and 6.4). Acidification of C5 caused a pH-dependent exposure of a C5a
neoepitope in C5, which was detected as C5a in the BD C5a-ELISA
(Fig. 2A). This was dependent on C5 since no detection occurred in C5-
deficient serum at any pH. Detection was independent of liberation of
C5a since there was no signal in the Hycult C5a-ELISA. Four mAbs,
binding to the C5b- or C5a-part of C5, were preincubated with normal
and acidified sera before analysis in the BD C5a ELISA. One of four
antibodies, clone 137-26, competitively inhibited detection (Fig. 2B).
The 137-26 clone binds to a C5a epitope exposed in the native C5
molecule, and neutralizes C5a before C5a is released (Fung et al.,
2003). These data indicate that the epitope detected by the BD C5a
ELISA is in close proximity to the 137-26 C5a epitope and explains the
false positive C5a results, by a conformational change in the C5a moiety
of C5 when binding eculizumab.
Treatment of patients with eculizumab is approved for the indica-
tions of PNH and aHUS, but eculizumab is also regularly administered
to patients in various off-label use (Castaneda-Sanabria et al., 2016).
There are solid data on efficient blockade of C5-cleavage by eculizumab
in patients with common polymorphisms in C5, however, patients
carrying any of the C5 Arg885His/Cys mutations are non-responders
(Nishimura et al., 2014) and recently, residual C5-cleavage was ob-
served ex vivo upon forceful complement activation with high surface
densities of C3b (Harder et al., 2017). Therefore, an accurate mon-
itoring of complement inhibition upon treatment is critical, which in
the case of eculizumab is further more complicated by individual var-
iations in clearance rate (Jodele et al., 2016; Wehling et al., 2016).
Here, we show that one of the most commonly used assays for C5a-
quantification, the BD OptEIA™ Human C5a ELISA Kit II, is not ap-
plicable for monitoring of eculizumab C5 inhibition since the eculi-
zumab-C5 complex induces a C5a neoepitope formation in the C5a-
domain of uncleaved C5, falsely detected as C5a in the assay.
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